1 February - “Lars Fruergaard Jørgensen, president and CEO: “2018 was a year of change and significant progress for Novo Nordisk. We delivered on our targets for sales and operating profit and have successfully launched Ozempic®, our new once-weekly GLP-1 for people with type 2 diabetes, in several countries. The results from the broad PIONEER phase 3a programme for oral semaglutide are very encouraging for people with type 2 diabetes, and we are now close to submitting oral semaglutide for FDA approval.”
Operating profit increased by 6% measured in local currencies when adjusted for the cost of severance and the priority review voucher for oral semaglutide
Sales remained broadly unchanged in Danish kroner and increased by 5% in local currencies to DKK 111.8 billion.
23 November - Novo Nordisk has announced the headline results from the last global phase 3a trial, PIONEER 6.
“We are very encouraged that PIONEER 6 demonstrated cardiovascular safety as well as a significant reduction in both CV and all-cause mortality following oral semaglutide treatment in people with type 2 diabetes at high cardiovascular risk. Based on the strong clinical data reported throughout the PIONEER clinical trial programme, we have now established a solid efficacy and safety profile for oral semaglutide and we are looking forward to sharing the results with regulatory authorities during 2019,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
Twenty years after Jacob Sten Petersen embarked upon a career in diabetes research, his own daughter Vita was diagnosed with type 1 diabetes. Here he reflects on his very personal motivation to achieve a cure for type 1 diabetes and on the progress of Novo Nordisk’s stem cell research.
Many more people are today affected by chronic non-communicable diseases (NCDs) than by communicable diseases. This is not reflected in resources for health in general and much less in humanitarian crises.
The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk have partnered to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world. Focus will be on ensuring efficient supply of low-cost human insulin in vials to Red Cross globally; support for ICRC’s and DRC’s health programmes; 2-3 projects to provide care to people with hypertension and diabetes in humanitarian crises to be conducted within three years.
Obesity can seem fairly straightforward to explain – if we consume more calories than we need, we pile on the pounds. But in fact, the problem is much more complex. It seems our bodies are hard-wired to hang on to those extra calories, probably because for thousands of years, it was a basic survival mechanism.
1 February - 2018 results
2 May - first quarter
9 August - first half
1 November - third quarter
Danish Government and Novo Nordisk have partnered with UN-anchored initiative on non-communicable diseases. The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.